Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies.
- 05/12/2025
|
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery.
- 04/30/2025
|
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Peter Ehrlich - AikenSalt Raghuram Selvaraju - HC Wainwright & Co Tim Dyer Hello everyone. I would like to thank you all for attending our 2024 Full Year Financial Results Conference Call.
- 04/25/2025
|
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
- Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate update.
- 04/25/2025
|
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated.
- 04/17/2025
|
Addex to Present at the 2025 Swiss Equities Baader Conference
- Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 08-10, 2025.
- 01/08/2025
|
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corporate Update Conference Call.
- 11/22/2024
|
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update.
- 11/22/2024
|
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
- Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
- 11/11/2024
|
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
- Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024.
- 11/11/2024
|
What Makes Addex Therapeutics (ADXN) a New Buy Stock
- Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 10/04/2024
|
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
- 09/30/2024
|
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.
- 09/30/2024
|
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024.
- 09/19/2024
|
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
- Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
- 09/06/2024
|
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.
- 09/04/2024
|
Addex Stock Soars on Crucial Update From Indivior Research Deal
- ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
- 08/28/2024
|
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
- U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
- 08/27/2024
|
Why Addex Therapeutics stock skyrocketed 70% on Tuesday
- Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
- 08/27/2024
|
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.
- 08/27/2024
|
Addex's Partner Discontinues ADX71149 development in Epilepsy
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.
- 07/22/2024
|
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.
- 07/15/2024
|
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
- Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.
- 07/12/2024
|
Addex Shareholders Approve All Resolutions at Annual General Meeting
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).
- 07/01/2024
|
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- ● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .
- 06/06/2024
|
Addex Convenes Annual General Meeting 2024
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
- 06/05/2024
|
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 05/31/2024
|
Addex to Present at Bio€quity Europe 2024
- Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
- 05/08/2024
|
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
- 04/29/2024
|
Addex to Present at the Swiss Biotech Day 2024
- Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.
- 04/19/2024
|
Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by.
- 04/18/2024
|
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
- 04/18/2024
|
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 04/11/2024
|
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, today announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
- 04/03/2024
|
Addex to Present at the Bio-Europe Spring 2024 Conference
- Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event.
- 03/14/2024
|
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C.
- 01/31/2024
|
Addex to Present at the Swiss Equities Baader Conference
- Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.
- 01/09/2024
|
Addex to Present at Biotech Showcase™ 2024
- CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024. In his presentation, scheduled for Monday January 8, 2024 at 4:30 PM PT (01:30 AM CET), Mr Dyer will provide a corporate update and discuss recent advances from Addex's CNS pipeline, including: ADX71149 in Phase 2 for epilepsy with Janssen Pharmaceuticals, Inc. Dipraglurant in post-stroke recovery GABAB PAM Indivior strategic partnership for substance use disorders M4 PAM schizophrenia program GABAB PAM cough program mGlu2NAM cognition program Presentation Details: Date: Monday, January 08 2024Time: 4:30PMTrack: Yosemite A (Ballroom Level) Mr Dyer will be available for one-on-one meetings throughout the conference.
- 01/05/2024
|
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors at its Extraordinary General Meeting (EGM) held on December 19, 2023.
- 12/20/2023
|
Addex Creates Treasury Shares
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that 15,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.
- 12/14/2023
|
Addex Therapeutics Ltd (ADXN) Q3 2023 Earnings Call Transcript
- Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Operator Good day and thank you for standing by.
- 11/29/2023
|
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
- ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars grant CHF 4.8M ($5.2M) of cash and cash equivalents at September 30, 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 29, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 2023 financial results for the period ended September 30, 2023 and provides a corporate update.
- 11/29/2023
|
Addex Convenes Extraordinary General Meeting
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that an Extraordinary General Meeting is convened and will take place on Tuesday December 19, 2023, at 11:00 am CET at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
- 11/28/2023
|
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
- Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.
- 11/23/2023
|
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
- Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study.
- 11/14/2023
|
Addex Regains Nasdaq Listing Compliance
- Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.
- 11/08/2023
|
Addex Announces Participation in the Bio-Europe 2023 Conference
- Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference (November 6 – 8, 2023) in Munich, Germany.
- 11/02/2023
|
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
- Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference (September 11 – 13, 2023) in New York.
- 09/06/2023
|
Addex Therapeutics Ltd (ADXN) Q2 2023 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Transition Science Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Operator Good day and thank you for standing by.
- 08/10/2023
|
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
- Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim Dyer, CEO, Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 08/04/2023
|
Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Call Transcript
- Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive Officer Robert Lütjens – Head of Discovery-Biology Conference Call Participants Boobalan Pachaiyappan – H.C.
- 05/12/2023
|
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
- Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 05/04/2023
|
Addex Therapeutics Ltd. (ADXN) Q4 2022 Earnings Call Transcript
- Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q4 2022 Results Conference Call March 30, 2023 10:00 AM ET Company Participants Timothy Dyer - CEO Robert Lutjens - Head, Discovery Biology Conference Call Participants Raghuram Selvaraju - H.C.
- 03/31/2023
|
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
- Geneva, Switzerland, March 2 8 , 20 2 3 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 03/28/2023
|
Addex Announces Upcoming Conferences it will participate for H1 2023
- Geneva, Switzerland, March 16, 202 3 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the first half of 2023:
- 03/16/2023
|
Addex Therapeutics Ltd (ADXN) Q3 2022 Earnings Call Transcript
- Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2022 Results Conference Call November 11, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Rob Lütjens - Head of Discovery, Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Tim Dyer Hello everyone. I'd like to thank you all for joining our Quarter Three 2022 Financial Results Conference Call.
- 11/11/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022.
- 11/11/2022
|
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Geneva, Switzerland, November 3 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its third quarter 2022 financial results on Friday, November 11, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 11:00 EDT / 08:00 PDT) the same day.
- 11/03/2022
|
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.
- 09/20/2022
|
Addex Therapeutics Ltd (ADXN) CEO Tim Dyer on Q2 2022 Results - Earnings Call Transcript
- Start Time: 10:00 January 1, 0000 10:41 AM ET Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2022 Earnings Conference Call August 18, 2022, 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call.
- 08/18/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022.
- 08/18/2022
|
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
- Geneva, Switzerland, August 12 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
- 08/12/2022
|
What's Happening With Addex Therapeutics Shares Today
- Addex Therapeutics Ltd (NASDAQ: ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share capital from CHF 1.00 to CHF 0.01 following the expiration of a period of two months after the third creditor call in The Swiss Gazette of.
- 07/21/2022
|
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
- Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.
- 06/17/2022
|
Why Shares Of Addex Therapeutics Are Falling Today
- Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ: ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment.
- 06/17/2022
|
Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why
- Addex Therapeutics Ltd (NASDAQ: ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. Data readout from the trial was expected in 1H of 2023.
- 06/17/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022.
- 05/05/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/29/2022
|
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call Transcript
- Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call Transcript
- 03/10/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021.
- 03/10/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 02/15/2022
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0.00% and 96.43%, respectively, for the quarter ended September 2021.
- 11/04/2021
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 10/26/2021
|
New Strong Sell Stocks for August 20th
- ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
- 08/20/2021
|
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Tops Revenue Estimates
- Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -18.46% and 352.31%, respectively, for the quarter ended June 2021.
- 08/05/2021
|
Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
- Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.
- 07/16/2021
|
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020 Results - Earnings Call Transcript
- Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Enamine Extend Collaboration With Prominent Swiss Biotech
- KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in med
- 02/24/2021
|
Why Addex, Genetic Technologies And Obalon Are Moving Today
- Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone. Genetic Technologies is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health.
- 01/21/2021
|
Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today
- Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today appeared first on InvestorPlace.
- 01/21/2021
|
ADXN Stock Price Increases Over 50% Pre-Market: Why It Happened
- The stock price of Addex Therapeutics (NASDAQ: ADXN) is trading at more than 50% pre-market today. This is why it happened.
- 01/21/2021
|
Addex Announces Pricing of $10.0 Million Global Offering
- Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 registered shares (the New Shares) (including shares in the form of American Depositary Shares, or ADSs) at a public offering price of approximately CHF1.47 per share or $10.00 per ADS. Each ADS represents the right to receive six shares of Addex. The aggregate gross proceeds from the offering are expected to be $10.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex. The offering is expected to close on or about January 11, 2021, subject to satisfaction of customary closing conditions.
- 01/06/2021
|
Addex Reports 2020 Half Year Financial Results and Provides Corporate Update
- Geneva, Switzerland, August 12, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its second quarter and half year financial results for the periods ended June 30, 2020 and provided an update on corporate activities. H1 2020 Operating Highlights: * Completed first half 2020 with a liquidity position of CHF 20.7 million of cash and cash equivalents * Announced ADX71149 (JNJ-40411813) to start Phase 2a study in epilepsy in early 2021 * Constituted scientific advisory board and appointed Darryle D. Schoepp PhD, one of the world’s leading and most successful neuroscience drug developers, as Chairman * Dipraglurant ready to start dosing patients in pivotal registration study in levodopa induced dyskinesia associated with Parkinson’s disease (PD-LID) once restrictions in US healthcare system associated with the global Covid-19 crisis are lifted * Advanced GABAB positive allosteric modulator (PAM) research program towards clinical candidate selection * Advanced mGlu7 negative allosteric modulator (NAM) research program towards clinical candidate selection * Listed American Depositary Shares (ADS) representing our ordinary shares on the Nasdaq Stock Market on January 29, 2020“During the first half, we have continued to execute on our strategy and add value to Addex. The decision by Janssen to advance ADX71149 (JNJ-40411813) into Phase 2 in 2021 is especially important as we now have two active clinical programs and a pipeline of earlier stage compounds advancing towards the clinic,” said Tim Dyer CEO of Addex. “We are particularly looking forward to the second half of 2020 as we hope to be able to dose the first patients in the planned pivotal study of dipraglurant in PD-LID.” Key Financial Data of the second quarter and the first half 2020:CHF’ thousands Q2 20 Q2 19 Change H1 20 H1 19 Change Income 933 525 408 1,885 1,227 658 R&D expenses (2,319) (3,411) 1,092 (5,872) (5,894) 22 G&A expenses (1,588) (1,478) (110) (3,260) (2,821) (439) Total operating loss (2,974) (4,364) 1,390 (7,247) (7,488) 241 Finance result, net (141) (136) (5) (174) (53) (121) Net loss for the period (3,115) (4,500) 1,385 (7,421) (7,541) 120 Basic and diluted net loss per share (0.12) (0.17) 0.05 (0.28) (0.29) 0.01 Net decrease in cash and cash equivalents (6,455) (2,111) (4,344) (10,506) (4,924) (5,582) Cash and cash equivalents as of June 30 20,671 36,748 (16,077) 20,671 36,748 (16,077) Shareholders’ equity as of June 30 18,801 32,273 (13,472) 18,801 32,273 (13,472) Financial SummaryIncome increased by CHF 0.7 million to CHF 1.9 million in the first half of 2020 compared to CHF 1.2 million in the first half of 2019, primarily due to research funding from Indivior under our GABAB PAM partnership. Of this increase in income, CHF 0.4 million was attributable to the second quarter 2020. Research and development expenses remained stable at CHF 5.9 million in the first half of 2020 compared to the first half of 2019 and related primarily to dipraglurant PD-LID and GABAB PAM programs. During the second quarter of 2020, these expenses decreased by CHF 1.1 million, compared to the second quarter of 2019 primarily due to reduced spending on dipraglurant PD-LID program following the suspension of initiation of the Phase 2b/3 pivotal study in PD-LID. G&A expenses increased by CHF 0.4 million to CHF 3.3 million in the first half of 2020, compared to CHF 2.8 million in the first half of 2019, primarily due to costs related to the listing of ADSs on the Nasdaq Stock Market. During the second quarter of 2020, G&A slightly increased by CHF 0.1 million compared to the second quarter of 2019 mainly due to ongoing costs associated with our US listing. The net loss for the first half 2020 was CHF 7.4 million compared to CHF 7.5 million for the first half of 2019 and CHF 3.2 million for the second quarter of 2020 compared to CHF 4.5 million for the same period in 2019.Basic and diluted loss per share decreased to CHF 0.28 for the first half of 2020, compared to CHF 0.29 for the first half of 2019. For the second quarter of 2020, the basic and diluted loss per share decreased to CHF 0.12 compared to CHF 0.17 for the second quarter 2019. Cash and cash equivalents amounted to CHF 20.7 million at June 30, 2020 compared to CHF 36.7 million at June 30, 2019 and CHF 31.5 million at December 31, 2019. The decrease was primarily due to cash used in operating activities. 2020 Condensed Consolidated Interim Financial Statements:The half year 2020 financial report can be found on the Company’s website in the investor/download section here.Conference Call Details:A conference call will be held today, Wednesday, August 12, 2020 at 4:00 p.m. CEST / 3:00 p.m BST / 10:00 a.m EST, to review the financial results. Tim Dyer, Chief Executive Officer; Roger Mills, Chief Medical officer; and Robert Lütjens, Co-Head of Discovery (Biology), will deliver a brief presentation followed by a Q&A session.Joining the Conference Call:1. In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.Dial-In Numbers: 1. Switzerland + 41445806522 2. UK + 442030092470 3. USA + 18774230830 4. Other countries’ numbers 5. Provide the operator with the Participant PIN Code: 22285484Joining the Live Event Online: 1. In the 10 minutes prior to the call start time, sign in online by following this Webex Link. 2. Password : Welcome About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is ready to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) subject to restrictions in US healthcare system associated with the global Covid-19 crisis being lifted. Addex is also investigating dipraglurant's therapeutic use in dystonia in preclinical models. Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration withJanssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in early 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Press Contacts:Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)20 7318 2955 msinclair@halsin.com Forward Looking Statements: Certain statements made in this announcement are forward-looking statements including with respect to the anticipated timing of the Company’s clinical trials and the reporting of data therefrom. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including relays resulting from the COVID-19 pandemic and healthcare regulatory considerations. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
- 08/12/2020
|
Addex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020
- Geneva, Switzerland, August 10, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2020 financial results, provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and the media on Wednesday, August 12 at 16:00 CEST (14:00 GMT/10:00 ET).Title: Addex Half-Year 2020 Financial Results Conference Call Date: August 12, 2020 Time: 16:00 CEST (14:00 GMT/10:00 ET)Joining the Conference Call:In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.Dial-in numbers: Switzerland: +41 44 58 06 522 United States: +1 877 4230830 United Kingdom: +44 203 0092470Link for other countries Participation Pin Code: 22285484Connect to live event: Link Password: WelcomeAbout Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models. Addex's second clinical program ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a Phase 2a proof of concept clinical study for the treatment of epilepsy. In addition, Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Press Contacts:Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)20 7318 2955 msinclair@halsin.com Forward Looking Statements: Certain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Company's shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
- 08/10/2020
|
Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020
- Geneva, Switzerland, August 6, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will participate in the BTIG Virtual Biotechnology Conference taking place on August 10 – 11, 2020.Mr. Dyer will participate and present Addex on August 10, 2020 at 10:30 AM ET. You can follow the event by following this link.Mr. Dyer will also be available for one-on-one meetings during the conference. Meetings can be requested via the BTIG virtual conference system for those who registered to participate. About Addex TherapeuticsAddex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models. Addex's second clinical program ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with our partner Janssen Pharmaceuticals, Inc., scheduled to enter a Phase 2a proof of concept clinical study for the treatment of epilepsy. In addition, Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Press Contacts:Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)20 7318 2955 msinclair@halsin.com Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
- 08/06/2020
|
Van Leeuwenhoeck Issues Updated Addex Equity Research Report
- Geneva, Switzerland, July 20, 2020 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that.
- 07/20/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization
- 03/24/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter
- 03/04/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
- 02/19/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- 02/14/2020
|
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- 02/13/2020
|
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
- 02/12/2020
|
